TN2009000331A1 - Derives de 3-amino-pyrrolo [3,4-c]pyrazole -5- (1h,4h,6h) carbaldehyde servant d'inhibiteurs de pkc - Google Patents
Derives de 3-amino-pyrrolo [3,4-c]pyrazole -5- (1h,4h,6h) carbaldehyde servant d'inhibiteurs de pkcInfo
- Publication number
- TN2009000331A1 TN2009000331A1 TNP2009000331A TN2009000331A TN2009000331A1 TN 2009000331 A1 TN2009000331 A1 TN 2009000331A1 TN P2009000331 A TNP2009000331 A TN P2009000331A TN 2009000331 A TN2009000331 A TN 2009000331A TN 2009000331 A1 TN2009000331 A1 TN 2009000331A1
- Authority
- TN
- Tunisia
- Prior art keywords
- pyrrolo
- pyrazole
- amino
- disease
- pkc inhibitors
- Prior art date
Links
- GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical class NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention concerne des composés et sels pharmaceutiquement acceptables de formules A et B : dans lesquelles A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9 et R10 répondent aux définitions précitées. L'invention concerne en outre des compositions pharmaceutiques comprenant les composés et sels pharmaceutiquement acceptables et des méthodes de traitement du diabète sucré et de ses complications, du cancer, d'une ischémie, de l'inflammation, de troubles du système nerveux central, d'une maladie cardiovasculaire, de la maladie d'Alzheimer et d'une maladie dermatologique, de maladies virales, de troubles inflammatoires, ou de maladies dans lesquelles le foie est un organe cible.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88874907P | 2007-02-07 | 2007-02-07 | |
| US98908607P | 2007-11-19 | 2007-11-19 | |
| US2096508P | 2008-01-14 | 2008-01-14 | |
| PCT/IB2008/000297 WO2008096260A1 (fr) | 2007-02-07 | 2008-02-04 | Nouveaux dérivés de 3-amino-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldéhyde |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2009000331A1 true TN2009000331A1 (fr) | 2010-12-31 |
Family
ID=39493354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2009000331A TN2009000331A1 (fr) | 2007-02-07 | 2009-08-05 | Derives de 3-amino-pyrrolo [3,4-c]pyrazole -5- (1h,4h,6h) carbaldehyde servant d'inhibiteurs de pkc |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US8183255B2 (fr) |
| EP (1) | EP2118112B1 (fr) |
| JP (1) | JP5161245B2 (fr) |
| KR (1) | KR101060892B1 (fr) |
| AP (1) | AP2009004958A0 (fr) |
| AU (1) | AU2008212625B2 (fr) |
| BR (1) | BRPI0807346B8 (fr) |
| CA (1) | CA2677572C (fr) |
| CR (1) | CR10968A (fr) |
| DO (1) | DOP2009000201A (fr) |
| EA (1) | EA017937B1 (fr) |
| EC (1) | ECSP099569A (fr) |
| IL (1) | IL200270A (fr) |
| MA (1) | MA31178B1 (fr) |
| MX (1) | MX2009008546A (fr) |
| NZ (1) | NZ578876A (fr) |
| TN (1) | TN2009000331A1 (fr) |
| WO (1) | WO2008096260A1 (fr) |
| ZA (1) | ZA200906032B (fr) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8183255B2 (en) | 2007-02-07 | 2012-05-22 | Pfizer, Inc. | N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors |
| WO2011090738A2 (fr) | 2009-12-29 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinase raf de type ii |
| WO2011107494A1 (fr) | 2010-03-03 | 2011-09-09 | Sanofi | Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation |
| WO2011157827A1 (fr) | 2010-06-18 | 2011-12-22 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2012112674A2 (fr) * | 2011-02-15 | 2012-08-23 | The Johns Hopkins University | Composés et procédés d'utilisation de ceux-ci dans le traitement de troubles neurodégénératifs |
| CN102093366B (zh) * | 2011-03-04 | 2012-11-28 | 中国医学科学院医药生物技术研究所 | 双环氨基吡唑类化合物及其在抗柯萨奇病毒中的应用 |
| EP2567959B1 (fr) | 2011-09-12 | 2014-04-16 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
| WO2013037390A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
| WO2013045413A1 (fr) | 2011-09-27 | 2013-04-04 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase |
| AU2012340200B2 (en) | 2011-11-17 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-Terminal Kinase (JNK) |
| WO2013152198A1 (fr) | 2012-04-04 | 2013-10-10 | Rigel Pharmaceuticals, Inc. | Inhibiteurs de protéine kinase c et utilisations de ceux-ci |
| CN106279202A (zh) * | 2012-05-03 | 2017-01-04 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂用于治疗帕金森病的吡唑氨基嘧啶衍生物 |
| EP2909194A1 (fr) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de cycline-dépendante kinase 7 (cdk7) |
| US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
| US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| WO2014151900A1 (fr) | 2013-03-14 | 2014-09-25 | Rigel Pharmaceuticals, Inc. | Inhibiteurs de protéine kinase c et leurs utilisations |
| AU2014337122B2 (en) | 2013-10-18 | 2019-01-03 | Dana-Farber Cancer Institute, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
| CN105849099B (zh) | 2013-10-18 | 2020-01-17 | 达纳-法伯癌症研究所股份有限公司 | 周期蛋白依赖性激酶7(cdk7)的多环抑制剂 |
| WO2015164604A1 (fr) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de janus kinase marqués de manière hydrophobe et utilisations associées |
| US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| JP2017516853A (ja) * | 2014-05-23 | 2017-06-22 | ミングサイト ファーマシューティカルズ，インク． | 自己免疫性疾患の処置 |
| US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| CA2986441A1 (fr) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Therapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases |
| WO2017044858A2 (fr) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinases cycline-dépendantes |
| CN111568905A (zh) * | 2015-11-20 | 2020-08-25 | 深圳明赛瑞霖药业有限公司 | 自身免疫疾病的治疗 |
| SG11201804210XA (en) * | 2015-11-20 | 2018-06-28 | Mingsight Pharmaceuticals Inc | Treatment of autoimmune disease |
| EP3484477B1 (fr) * | 2016-07-14 | 2023-09-13 | Mingsight Pharmaceuticals, Inc. | Traitement du cancer |
| CN108929325A (zh) | 2017-05-25 | 2018-12-04 | 深圳明赛瑞霖药业有限公司 | Pkc抑制剂固态形式 |
| MA50356A (fr) | 2017-10-11 | 2021-04-21 | Hoffmann La Roche | Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1 |
| US20210069194A1 (en) * | 2018-01-17 | 2021-03-11 | Mingsight Pharmaceuticals, Inc. | Combination therapy for the treatment of cancer |
| AU2019295632B2 (en) | 2018-06-25 | 2025-03-06 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
| WO2020140098A1 (fr) * | 2018-12-28 | 2020-07-02 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de la kinase dépendante des cyclines 7 et leurs utilisations |
| WO2022261214A1 (fr) * | 2021-06-09 | 2022-12-15 | Mingsight Pharmaceuticals, Inc. | Compositions comprenant des inhibiteurs de pkc-bêta et procédés de préparation associés |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200301813B (en) | 2000-08-10 | 2004-06-22 | Pharmacia Italia Spa | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them. |
| UA81790C2 (uk) | 2002-12-19 | 2008-02-11 | Фармация Италия С.П.А. | Заміщені піролопіразольні похідні як інгібітори кінази |
| RS51891B (en) | 2005-01-10 | 2012-02-29 | Pfizer Inc. | PIROLOPIRAZOLI, POTENTNI INHIBITORI KINAZE |
| US8183255B2 (en) | 2007-02-07 | 2012-05-22 | Pfizer, Inc. | N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors |
-
2008
- 2008-02-04 US US12/523,965 patent/US8183255B2/en active Active
- 2008-02-04 NZ NZ578876A patent/NZ578876A/xx unknown
- 2008-02-04 JP JP2009548766A patent/JP5161245B2/ja active Active
- 2008-02-04 KR KR1020097018673A patent/KR101060892B1/ko active Active
- 2008-02-04 EP EP08702370.1A patent/EP2118112B1/fr active Active
- 2008-02-04 AP AP2009004958A patent/AP2009004958A0/xx unknown
- 2008-02-04 MX MX2009008546A patent/MX2009008546A/es active IP Right Grant
- 2008-02-04 EA EA200970670A patent/EA017937B1/ru not_active IP Right Cessation
- 2008-02-04 AU AU2008212625A patent/AU2008212625B2/en active Active
- 2008-02-04 CA CA2677572A patent/CA2677572C/fr active Active
- 2008-02-04 WO PCT/IB2008/000297 patent/WO2008096260A1/fr active Application Filing
- 2008-02-04 BR BRPI0807346A patent/BRPI0807346B8/pt active IP Right Grant
-
2009
- 2009-08-05 TN TNP2009000331A patent/TN2009000331A1/fr unknown
- 2009-08-06 IL IL200270A patent/IL200270A/en not_active IP Right Cessation
- 2009-08-06 CR CR10968A patent/CR10968A/es unknown
- 2009-08-07 EC EC2009009569A patent/ECSP099569A/es unknown
- 2009-08-07 DO DO2009000201A patent/DOP2009000201A/es unknown
- 2009-08-07 MA MA32158A patent/MA31178B1/fr unknown
- 2009-08-31 ZA ZA2009/06032A patent/ZA200906032B/en unknown
-
2012
- 2012-04-18 US US13/450,388 patent/US8877761B2/en active Active
-
2014
- 2014-10-03 US US14/506,470 patent/US9518060B2/en active Active
-
2016
- 2016-12-12 US US15/376,279 patent/US10316045B2/en active Active
-
2019
- 2019-04-17 US US16/387,369 patent/US11220518B2/en active Active
-
2021
- 2021-12-01 US US17/539,948 patent/US11780853B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2009000331A1 (fr) | Derives de 3-amino-pyrrolo [3,4-c]pyrazole -5- (1h,4h,6h) carbaldehyde servant d'inhibiteurs de pkc | |
| MX2009010951A (es) | Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)-carbaldehid o como inhibidores de proteina quinasa c. | |
| US6624202B2 (en) | Inhibitors of copper-containing amine oxidases | |
| DE60103974T2 (de) | Gyrase-inhibitoren und ihre verwendung | |
| TWI577681B (zh) | 咪唑并嗒化合物 | |
| DE602004028150D1 (de) | Aminopyrazolderivate als gsk-3-inhibitoren | |
| ATE537175T1 (de) | Neue piperazino-dihydrothienopyrimidin-derivate | |
| CA2662848C (fr) | Derives de 2-aryl-6-phenyl-imidazo[1,2-.alpha.]pyridines, leur preparation et leur application en therapeutique | |
| MA38138A1 (fr) | Dérivés inédits de quinolone | |
| TN2013000393A1 (fr) | Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase | |
| MA30821B1 (fr) | Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes | |
| TN2011000252A1 (fr) | Lactames servant d'inhibiteurs de beta-secretase | |
| TN2009000483A1 (fr) | Derives de 7-alkynyl-1-8-naphthyridones, leur preparation et leur application en therapeutique | |
| UA96618C2 (en) | 3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors | |
| JP7405756B2 (ja) | ピロリジンアミド誘導体及びその使用 | |
| EP2150550A4 (fr) | Nouveau composé carbamoyloxy aryle alcane arylpipérazine, compositions pharmaceutiques comprenant ce composé et méthode de traitement de la douleur, de l'anxiété et de la dépression par administration de ce composé | |
| MA27716A1 (fr) | 4-aminopyrimidine-5-one | |
| TNSN08138A1 (fr) | Derives d'imidazole pour le traitement de troubles neurologiques | |
| CN106986859B (zh) | 吲哚衍生物及其用途 | |
| WO2005080319A1 (fr) | Derives d'hydrazino alcool utiles en tant qu'inhibiteurs d'amine-oxydases contenant du cuivre | |
| JP2001523659A (ja) | 細胞外グルタミン酸濃度を低下させるための４位置換２−ピロリジノン誘導体 | |
| BRPI0704074B8 (pt) | derivados piperidínicos da (-)-cassina e (-)-spectalina, composições farmacêuticas contendo os mesmos e processos para sua preparação | |
| KR20090100443A (ko) | 심혈관 질환 치료용 1,3-디히드로이미다졸 | |
| MA52370B1 (fr) | Dérivés de la pyridine et leurs utilisations thérapeutiques comme inhibiteurs du trpc6 | |
| MA37678B2 (fr) | Nouvelles 7h-pyrrolo[2,3-d]pyrimidines substituées par un groupe amino en position 4, utilisées comme inhibiteurs de lrrk2 |